Valeant Pharmaceuticals International (VRX) announced Monday that it agreed to acquire Bausch & Lomb for $8.7 billion in cash.
The company also announced Tuesday that it received a Complete Response Letter from the FDA regarding its New Drug Application for efinaconazole for the treatment of onychomycosis.
Valeant Pharmaceuticals gapped open sharply higher Tuesday, but retreated during the first half of the morning, before settling into a range. Shares finished up by 7.33 at $91.80 on strong volume. The stock rose to its second consecutive new high for the year.
For comments and feedback: editorial@rttnews.com